CX 1739

Drug Profile

CX 1739

Alternative Names: CX-1739

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute on Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias; Mood stabilisers; Respiratory stimulants
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory insufficiency; Sleep apnoea syndrome
  • Preclinical Drug abuse
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 06 Jan 2017 RespireRx Pharmaceuticals plans a phase II trial Sleep apnoea syndrome (Opioid induced)
  • 06 Jan 2017 RespireRx Pharmaceuticals plans to re-commence the clinical development program of CX717 for Respiratory distress associated with spinal cord injury
  • 12 Sep 2016 Preliminary top-line safety and efficacy results from a phase IIa trial in Respiratory insufficiency were released by RespireRX Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top